The discreet device is placed on the patient with as few as three electrodes.
Equipped with the Cinterion MC75i module, the Aera-CT device enables communication of detailed diagnostic data via cellular networks and the Internet, providing patients and their physicians with 24/7 monitoring and improved detection and visibility of arrhythmia events.
The device is expected to be commercially available in North America in Q3 2011 followed by rolling launches throughout the world.